TARGETING THERANOSTICS AND MOLECULAR ONCOLOGY

Under the confident leadership of Group Director Molecular Oncology, Julie Crouch, 2022 marked significant progress in the development of Icon’s global theranostics program. Icon Cancer Centre North Lakes in Brisbane’s northern suburbs will be the Group’s first centre to offer a comprehensive theranostics service set to be operational in 2023. The centre has the infrastructure and resources to support both a clinical service and provide patients with access to quality clinical trials that contribute to developments in hyper-personalised cancer treatments.

The oncology segment market for theranostics is expected to grow to an excess of $129 billion by 2025, providing a significant pipeline of industry funded clinical trials. There is extensive interest from pharmaceutical companies in the field of molecular oncology who are interested in partnering with Icon to deliver theranostics clinical trials. Over the next 18 months, Icon has a pipeline of locations that will provide theranostics services and continued conversation with industry partners to activate theranostics trials across Australia and Singapore.

First Icon Theranostics Program to begin operations in 2023

Adelaide, South Australia site selected for Telix solid tumour trial

Theranostics trials under review in Icon Singapore

Molecular Oncology Practice Unit

The Molecular Oncology Practice Unit (MOPU) was formed in September 2022 to support the molecular oncology strategy to initially include theranostics, interventional oncology, and radiopharmacy. The membership of the MOPU includes representatives from quality and risk, research, nursing, pharmacy, medical physics, and nuclear medicine, providing a broad scope of expertise. Research and clinical trials are currently being discussed and assessed at the forum, setting the strategic agenda. A Theranostics Research Committee will commence in 2023.

Telix Solid Tumours Trial

Icon Cancer Centre Adelaide in South Australia has been selected as the lead private site for the Telix Solid Tumours study with CRO Novotech. This is a Phase 1b Dose Escalation/Expansion study of the combination of 177Lu-TLX250 and peposertib in patients with carbonic anhydrase IX (CAIX) expressing solid tumours. This trial is expected to commence in the second quarter of 2023 and executed in collaboration with Jones Radiology.

Novartis Theranostics Trials

Singapore has two potential theranostics trials under review; the Novartis phase 111 AAA603D1230 breast trial is a study of [177Lu]Lu-NeoB in combination with capecitabine versus capecitabine alone for the treatment of post-menopausal women with hormonal receptor-positive, human epidermal growth receptor-2 negative metastatic breast cancer after progression on previous endocrine therapy in combination with a CDK4/6 inhibitor. Novartis phase 111 CAAA603E1230 glioblastoma trial, a study of [177Lu]Lu-NeoB versus Lomustine for the treatment of Recurrent Glioblastoma. Icon looks forward to further collaboration with Novartis in 2023 and beyond in this exciting new area of treatment and research.